|1.||Kobayashi, Motohiro: 9 articles (09/2007 - 01/2002)|
|2.||Natsume, Tsugitaka: 7 articles (09/2007 - 01/2002)|
|3.||Watanabe, Junichi: 5 articles (09/2007 - 05/2006)|
|4.||Natsume, T: 5 articles (11/2006 - 08/2000)|
|5.||Kobayashi, M: 4 articles (07/2001 - 08/2000)|
|6.||Fukuoka, Masahiro: 2 articles (02/2009 - 07/2007)|
|7.||Rawat, Diwan S: 2 articles (08/2008 - 01/2006)|
|8.||Joshi, Penny: 2 articles (08/2008 - 01/2006)|
|9.||Feit, Kevie: 2 articles (02/2007 - 12/2006)|
|10.||Nishio, K: 2 articles (11/2006 - 01/2001)|
05/01/1998 - "When given in combination, auristatin PE + bryostatin 1-treated animals were all free of tumors (five of five) for 150 days and were considered cured. "
02/01/2009 - "A phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT-1027, and to assess its pharmacokinetic profile in Japanese patients with advanced solid tumors following administration of the drug weekly for 3 weeks. "
05/15/2005 - "The objectives of this phase I study was to assess the dose-limiting toxicities (DLT), to determine the maximum tolerated dose, and to study the pharmacokinetics of TZT-1027 when given i.v. over 60 minutes on days 1 and 8 every 3 weeks to patients with advanced solid tumors. "
10/01/2001 - "In an earlier study we reported a potent antitumor activity of Auristatin PE (AuriPE) against pancreatic tumor. "
03/01/2000 - "These results suggest that TZT-1027 is an excellent candidate for clinical trials for the treatment of cancer."
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
06/01/1999 - "From these results, we conclude that the selection of therapeutic agents based on their molecular mechanism may improve therapeutic outcome, and that auristatin-PE may be more effective in the treatment of pancreatic cancer when given in combination with gemcitabine, rather than as a single agent."
06/01/1999 - "Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine."
06/01/1999 - "In this study, we investigated the molecular mechanisms by which auristatin-PE, a newly developed experimental agent, and gemcitabine, a commercially available anti-cancer agent, exert their inhibitory effects on pancreatic cancer cell lines containing wild-type p53 (HPAC) and mutant p53 (PANC-1). "
04/01/1998 - "We conclude that the combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gemcitabine or auristatin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials."
07/15/2001 - "Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma."
07/15/2001 - "To elucidate whether a novel antimicrotubule agent, TZT-1027, is influenced by the p53 status of tumors, the authors investigated the sensitivities of specimens obtained from patients with nonsmall cell lung carcinoma (NSCLC) and renal cell carcinoma (RCC) to various anticancer agents, including TZT-1027, and the status of the p53 gene in those specimens. "
10/01/1999 - "TZT-1027 induced apoptosis within 24 h, not only in human leukemia cells such as HL-60, but also in solid tumors such as human prostate carcinoma cells DU145 and human mammary carcinoma cells MCF-7. "
03/01/1997 - "TZT-1027 was also effective against human xenografts, that is, tumor regression was observed in mice bearing MX-1 breast and LX-1 lung carcinomas. "
03/01/1997 - "TZT-1027 was effective against P388 leukemia not only when administered i.p., but also when given i.v. However, although TZT-1027 given i.v. was active against murine solid tumors, TZT-1027 administered i.p. "
03/01/1997 - "Intermittent injections of TZT-1027 were more effective than single or repeated injections in mice with P388 leukemia and B16 melanoma. "
03/01/1997 - "In experiments with drug-resistant P388 leukemia, TZT-1027 showed good activity against cisplatin-resistant P388 and moderate activity against vincristine- and 5-fluorouracil-resistant P388, but no activity against adriamycin-resistant P388. "
03/01/2006 - "Two in vivo antitumor models, the murine P388 leukemia ascites tumor model and the human non-small cell lung cancer A549 solid tumor model, were used and cisplatin (CDDP), gemcitabine (GEM), irinotecan hydrochloride (CPT-11), fluorouracil (5-FU), paclitaxel (PTX) and docetaxel (DTX) were selected to be combined with TZT-1027. "
|3.||K 76 carboxylic acid
|4.||2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)